MedTrace Logo

Fractional Laser as Treatment Option for Various Pigment Disorders (Fractional-3)

NCT01085279 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2010-03-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether the use of non-ablative fractional laser is safe and effective in the treatment of melasma.

Conditions

  • Pigmentation Disorder

Interventions

DEVICE

Fraxel Restore, Solta Medical Inc. (Non-ablative fractional laser)

1,550 nm non-ablative fractional laser Irradiance: 15 mJ/microbeam. Coverage: 14-20%. Number of treatment sessions: 4-5

DRUG

Modified Kligman's formula (Triple topical therapy)

Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks

Sponsors & Collaborators

  • Netherlands Institute for Pigment Disorders

    lead OTHER

Principal Investigators

  • Albert Wolkerstorfer, MD PhD · Netherlands Institute for Pigment Disorders

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01085279 on ClinicalTrials.gov